1
|
Huang SB, Thapa D, Munoz AR, Hussain SS, Yang X, Bedolla RG, Osmulski P, Gaczynska ME, Lai Z, Chiu YC, Wang LJ, Chen Y, Rivas P, Shudde C, Reddick RL, Miyamoto H, Ghosh R, Kumar AP. Androgen deprivation-induced elevated nuclear SIRT1 promotes prostate tumor cell survival by reactivation of AR signaling. Cancer Lett 2021; 505:24-36. [PMID: 33617947 DOI: 10.1016/j.canlet.2021.02.008] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2020] [Revised: 02/03/2021] [Accepted: 02/10/2021] [Indexed: 12/24/2022]
Abstract
The NAD+-dependent deacetylase, Sirtuin 1 (SIRT1) is involved in prostate cancer pathogenesis. However, the actual contribution is unclear as some reports propose a protective role while others suggest it is harmful. We provide evidence for a contextual role for SIRT1 in prostate cancer. Our data show that (i) mice orthotopically implanted with SIRT1-silenced LNCaP cells produced smaller tumors; (ii) SIRT1 suppression mimicked AR inhibitory effects in hormone responsive LNCaP cells; and (iii) caused significant reduction in gene signatures associated with E2F and MYC targets in AR-null PC-3 and E2F and mTORC1 signaling in castrate-resistant ARv7 positive 22Rv1 cells. Our findings further show increased nuclear SIRT1 (nSIRT1) protein under androgen-depleted relative to androgen-replete conditions in prostate cancer cell lines. Silencing SIRT1 resulted in decreased recruitment of AR to PSA enhancer selectively under androgen-deprivation conditions. Prostate cancer outcome data show that patients with higher levels of nSIRT1 progress to advanced disease relative to patients with low nSIRT1 levels. Collectively, we demonstrate that lowering SIRT1 levels potentially provides new avenues to effectively prevent prostate cancer recurrence.
Collapse
Affiliation(s)
- Shih-Bo Huang
- Department of Urology, The University of Texas Health, USA
| | - D Thapa
- Department of Urology, The University of Texas Health, USA
| | - A R Munoz
- Department of Urology, The University of Texas Health, USA
| | - S S Hussain
- Department of Urology, The University of Texas Health, USA
| | - X Yang
- Department of Urology, The University of Texas Health, USA
| | - R G Bedolla
- Department of Urology, The University of Texas Health, USA
| | - P Osmulski
- Department ofMolecular Medicine, The University of Texas Health, USA
| | - M E Gaczynska
- Department ofMolecular Medicine, The University of Texas Health, USA
| | - Z Lai
- Department ofMolecular Medicine, The University of Texas Health, USA; Greehey Children's Cancer Research Institute, San Antonio, TX, 78229, USA
| | - Yu-Chiao Chiu
- Greehey Children's Cancer Research Institute, San Antonio, TX, 78229, USA
| | - Li-Ju Wang
- Greehey Children's Cancer Research Institute, San Antonio, TX, 78229, USA
| | - Y Chen
- Department ofEpidemiology and Biostatistics, The University of Texas Health, USA; Mays Cancer Center, San Antonio, TX, 78229, USA; Greehey Children's Cancer Research Institute, San Antonio, TX, 78229, USA
| | - P Rivas
- Department of Urology, The University of Texas Health, USA
| | - C Shudde
- Department of Urology, The University of Texas Health, USA
| | - R L Reddick
- Department ofPathology, The University of Texas Health, USA
| | - H Miyamoto
- Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, 14642, USA
| | - R Ghosh
- Department of Urology, The University of Texas Health, USA; Department ofMolecular Medicine, The University of Texas Health, USA; Mays Cancer Center, San Antonio, TX, 78229, USA
| | - A P Kumar
- Department of Urology, The University of Texas Health, USA; Department ofMolecular Medicine, The University of Texas Health, USA; South Texas Veterans Health Care System, San Antonio, TX, 78229, USA; Mays Cancer Center, San Antonio, TX, 78229, USA.
| |
Collapse
|
2
|
Greenough MA, Ramírez Munoz A, Bush AI, Opazo CM. Metallo-pathways to Alzheimer's disease: lessons from genetic disorders of copper trafficking. Metallomics 2016; 8:831-9. [PMID: 27397642 DOI: 10.1039/c6mt00095a] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Copper is an essential metal ion that provides catalytic function to numerous enzymes and also regulates neurotransmission and intracellular signaling. Conversely, a deficiency or excess of copper can cause chronic disease in humans. Menkes and Wilson disease are two rare heritable disorders of copper transport that are characterized by copper deficiency and copper overload, respectively. Changes to copper status are also a common feature of several neurodegenerative disorders including Alzheimer's disease (AD), Parkinson's disease (PD) and Amyotrophic lateral sclerosis (ALS). In the case of AD, which is characterized by brain copper depletion, changes in the distribution of copper has been linked with various aspects of the disease process; protein aggregation, defective protein degradation, oxidative stress, inflammation and mitochondrial dysfunction. Although AD is a multifactorial disease that is likely caused by a breakdown in multiple cellular pathways, copper and other metal ions such as iron and zinc play a central role in many of these cellular processes. Pioneering work by researchers who have studied relatively rare copper transport diseases has shed light on potential metal ion related disease mechanisms in other forms of neurodegeneration such as AD.
Collapse
Affiliation(s)
- M A Greenough
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria 3010, Australia.
| | | | | | | |
Collapse
|